Evaluating Software for Clinical Trials

With many statistical software packages available, I’m curious about how others assess the suitability of these tools for managing clinical trial data. I’ve recently used SAS for a phase II trial and found its capabilities robust, but I’m interested in comparing it with R for future studies. How do you choose your tools based on data interpretation needs?

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍‌⁠‌‍​⁠‌⁠​‍‌‍‍‍​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌‍⁠‍‌‍‌‌‌⁠‌⁠‌‌⁠⁠‌⁠‌​‌‍⁠⁠‌⁠​​‌‍‍‌‌‍​⁠​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​‍​‍‌‍⁠‍‌‍‌‌‌⁠‌⁠​‍​‍​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠‌‌​⁠​​​⁠‌⁠​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍​⁠‍​‌‍​‍‌‌⁠⁠‌​‌‌​⁠​​‌⁠‌⁠‌⁠​⁠‌‌‌‌‌‌‌‌‌​‍​‌‌​​‌‌‍‌‌⁠​‍‌‌‌‌‌‍​⁠‌⁠​‌​‍​‍‌⁠⁠‌​

I switched from SAS to R for my last trial and found R’s visualization tools really helped in presenting complex data clearly. Have you considered the learning curve for R? It can be a bit steep at first.

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍‌⁠‌‍​⁠‌⁠​‍‌‍‍‍​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠‍‌​⁠‌‍​⁠‌⁠​⁠‌‌​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠‌‌​⁠​‌​⁠​‌​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍​⁠​‌‌⁠‍​​⁠​‍‌⁠‌​‌‍‌‍​⁠‍​​‍⁠‌‌⁠​​‌​⁠‍‌​‍‌‌‌‍‍‌​​⁠‌‍‍‍​⁠​​‌⁠​​​⁠‍​​‍​‍‌⁠⁠‌

It’s interesting that you found SAS robust; it definitely has its strengths. R’s flexibility for complex visualizations is a game-changer, but keep an eye on that steep learning curve — it’s like learning to ride a bike without training wheels! Have you thought about how your team’s experience might influence your choice?

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍‌⁠‌‍​⁠‌⁠​‍‌‍‍‍​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠‍‌​⁠‌‍​⁠‌⁠​⁠‌‌​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠‌‌​⁠​‌​⁠‌⁠​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌‌‌⁠‌‌‌​‌​‌​‌​‍‌‌⁠‌‍‌‍‌​‌​‌​‌‌‍‍‌​​‍‌‍​⁠‌‍‌‍​⁠​⁠​⁠‌⁠‌​‌‌‌⁠​​‌‌​​​‍​‍‌⁠⁠‌